Chan YH, Chen SW, Chao TF, et al. - In this study, the impact of initial decline in estimated glomerular filtration rate (eGFR) in patients with type 2 diabetes (T2D) following sodium-glucose co-transporter-2 inhibitor (SGLT2i) treatment was explored. Researchers applied medical data from a multicentre healthcare provider in Taiwan and included 11,769 patients with T2D with baseline/follow-up eGFR data available after 1 to 3 months of SGLT2i treatment from 1 June 2016 to 31 December 2018. Evidence suggested that among patients with T2D, a pronounced eGFR decline of more than 30% following SGLT2i treatment was correlated with adverse cardiovascular or renal events.